Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other liabilities | — | (311) |
| Net cash used in operating activities | (89,801) | (54,521) |
| Investing Activities | ||
| Purchase of property and equipment | (262) | (22,358) |
| Purchase of marketable securities | (306,955) | (252,496) |
| Proceeds from maturities of marketable securities | 104,000 | 61,000 |
| Net cash used in investing activities | (203,217) | (213,854) |
| Financing Activities |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s capex?
- Eikon Therapeutics, Inc. (EIKN) reported capex of $262K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Eikon Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude